传统的化疗像是“无差别的轰炸”，杀灭癌细胞但是对正常细胞也有伤害；而靶向治疗和免疫治疗则像“精确制导”，但部分患者仍会耐药。HLX43是一种靶向PD-L1的抗体偶联药物（ADC），它巧妙地将两种策略结合在一起： ...

αPD-L1免疫检查点阻断虽已在临床取得进展，但总体应答率仍偏低。其主要原因在于免疫抑制性的肿瘤微环境：肿瘤血管结构异常导致灌注不足、缺氧和间质压升高，阻碍免疫细胞进入肿瘤，促使免疫抑制信号增强；同时，持续抗原刺激与抑制通路累积会推动T细胞耗竭，降低 ...

以 PD-1/PD-L1 抑制剂为代表的免疫治疗，是肿瘤治疗领域的里程碑式突破，却始终被耐药难题掣肘 —— 超半数患者会出现原发性或继发性耐药，无法从治疗中获益。 2022 年，FDA 批准了 Relatlimab（抗 LAG-3）联合 ...

Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according ...

Without any doubt, immune checkpoint inhibition has revolutionized the management of patients with metastatic melanoma, dramatically improving their prognosis, and is considered the standard treatment ...

AI may calculate PD-L1 scores for non-small cell lung cancer more accurately than manual assessment, results of an analysis ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...

De-escalating immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC) by cutting the dose, duration, and frequency of administration could optimize treatment efficacy, reduce ...

The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. This time, the agency is considering limiting these immunotherapies’ use in stomach cancer and esophageal ...